These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

93 related items for PubMed ID: 20399947

  • 1. Extended case-control study results on thromboembolic outcomes among transdermal contraceptive users.
    Dore DD, Norman H, Loughlin J, Seeger JD.
    Contraception; 2010 May; 81(5):408-13. PubMed ID: 20399947
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Venous thromboembolism, myocardial infarction, and stroke among transdermal contraceptive system users.
    Cole JA, Norman H, Doherty M, Walker AM.
    Obstet Gynecol; 2007 Feb; 109(2 Pt 1):339-46. PubMed ID: 17267834
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Recent combined hormonal contraceptives (CHCs) and the risk of thromboembolism and other cardiovascular events in new users.
    Sidney S, Cheetham TC, Connell FA, Ouellet-Hellstrom R, Graham DJ, Davis D, Sorel M, Quesenberry CP, Cooper WO.
    Contraception; 2013 Jan; 87(1):93-100. PubMed ID: 23083525
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Use of oral contraceptives containing gestodene and risk of venous thromboembolism: outlook 10 years after the third-generation "pill scare".
    Heinemann LA, Dinger JC, Assmann A, Minh TD.
    Contraception; 2010 May; 81(5):401-7. PubMed ID: 20399946
    [Abstract] [Full Text] [Related]

  • 12. Venous thromboembolic disease in users of low-estrogen combined estrogen-progestin oral contraceptives.
    Sidney S, Petitti DB, Soff GA, Cundiff DL, Tolan KK, Quesenberry CP.
    Contraception; 2004 Jul; 70(1):3-10. PubMed ID: 15208046
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Effects of oral and transdermal hormonal contraception on vascular risk markers: a randomized controlled trial.
    Johnson JV, Lowell J, Badger GJ, Rosing J, Tchaikovski S, Cushman M.
    Obstet Gynecol; 2008 Feb; 111(2 Pt 1):278-84. PubMed ID: 18238963
    [Abstract] [Full Text] [Related]

  • 17. Postmarketing study of ORTHO EVRA and levonorgestrel oral contraceptives containing hormonal contraceptives with 30 mcg of ethinyl estradiol in relation to nonfatal venous thromboembolism.
    Jick SS, Hagberg KW, Hernandez RK, Kaye JA.
    Contraception; 2010 Jan; 81(1):16-21. PubMed ID: 20004268
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Clinical experience with a new norgestimate-containing oral contraceptive.
    Huber J.
    Int J Fertil; 1992 Jan; 37 Suppl 1():47-53. PubMed ID: 1347520
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.